Endothelin: what does the radiologist need to know?
Endothelin (ET) is a potent endogenous vasoconstrictor peptide. It has been implicated in various pathological states since its discovery in 1988. The cardiovascular system and the kidneys are important sites for the action of this peptide. Two types of ET receptor, ETA and ETB, govern the biological effects of ET. Drugs that can prevent the endogenous synthesis of ET or block its binding to receptors may offer important therapeutic impact to patients with congestive heart failure, pulmonary hypertension and acute renal failure. Areas of particular interest to the radiologist include the role of ET in mediating some of the side effects of contrast media, particularly contrast medium nephropathy, and the involvement of ET in the pathogenesis of restenosis following angioplasty. This review outlines the basic biology of this important mediator and its role in health and disease.
Oldroyd
S D
SD
Sheffield Kidney Institute, Northern General Hospital Trust, UK.
Morcos
S K
SK
D000800:Angioplasty, Balloon; D001157:Arterial Occlusive Diseases / Q000628:therapy; D003287:Contrast Media / Q000009:adverse effects*; D016232:Endothelins / Q000502:physiology*; D006801:Humans; D017466:Receptors, Endothelin / Q000502:physiology; D012008:Recurrence
D003287:Contrast Media; D016232:Endothelins; D017466:Receptors, Endothelin